Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

@inproceedings{Wind2017ClinicalPA,
  title={Clinical Pharmacokinetics and Pharmacodynamics of Afatinib},
  author={Sven Wind and David Schnell and Thomas Ebner and Matthias Freiwald and Peter Stopfer},
  booktitle={Clinical pharmacokinetics},
  year={2017}
}
Afatinib is an oral, irreversible ErbB family blocker that covalently binds to the kinase domains of epidermal growth factor receptor (EGFR), human EGFRs (HER) 2, and HER4, resulting in irreversible inhibition of tyrosine kinase autophosphorylation. Studies in healthy volunteers and patients with advanced solid tumours have shown that once-daily afatinib has time-independent pharmacokinetic characteristics. Maximum plasma concentrations of afatinib are reached approximately 2-5 h after oral… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS